Myeloablative allogeneic stem cell transplant for AML and MDS: the impact of advanced age in the outcome

被引：0
|
作者：
Sanchez-Escamilla, M. [1 ,2 ]
Garcia-Avila, S. [1 ]
Yanez San Segundo, L. [1 ,2 ]
Bermudez Rodriguez, M. A. [1 ,2 ]
Colorado Araujo, M. M. [1 ,2 ]
Casado Diez, A. [1 ]
Celis Alvarez, M. [1 ]
Cabero Martinez, A. [1 ]
Fernandez Martinez, C. [1 ]
Insunza Garminde, A. [1 ,2 ]
Richard Espiga, C. [1 ,2 ]
Conde Garcia, E. [1 ,2 ]
机构：
[1] Marques de Valdecilla Univ Hosp, Santander, Spain
[2] IDIVAL, Santander, Spain
来源：
BONE MARROW TRANSPLANTATION | 2017年 / 52卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P415
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [21] Impact of Cytogenetics on Outcome of AML after Allogeneic Hematopoietic Stem Cell Transplantation
    Gindina, Tatiana L.
    Mamaev, Nikolay N.
    Afanasyev, Boris V.
    Bondarenko, Sergey N.
    Alyanskiy, Alexander
    Slesarchuk, Olga
    Moiseev, Ivan S.
    Razumova, Svetlana V.
    Zubarovskaya, Lyudmila
    BLOOD, 2015, 126 (23)
  • [22] The outcome of allogeneic stem cell transplantation in patients with high risk MDS and AML: single center experience
    Halahleh, Khalid
    Odaily, Sarah
    Al Tell, Abdallah
    Al-Awabdeh, Tala
    Ma'kosa, Mohammad
    Najjar, Rula
    Rihani, Rawad
    Abu Shanab, Mayada
    Hussein, Nilly
    Khattab, Eman
    Sharma, Shanta
    Abu Khader, Ahmad
    Yousef, Dana
    Abu-Jazar, Husam
    Tbakhi, Abdelghani
    Sarhan, Mahmoud
    BONE MARROW TRANSPLANTATION, 2018, 53 : 189 - 190
  • [23] A Single Institution Study of Allogeneic Hematopoietic Stem Cell Transplant for MDS and AML in Patients 60 Years of Age and Older: Impact of Disease Risk Index and Secondary Disease
    Gupta, Eva
    Hoffman, Randi
    Colleen, Thomas
    Hogan, William J.
    Litzow, Mark R.
    Sproat, Lisa
    Foran, James M.
    Finn, Laura E.
    Roy, Vivek
    BLOOD, 2015, 126 (23)
  • [24] Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
    Luger, S. M.
    Ringden, O.
    Zhang, M-J
    Perez, W. S.
    Bishop, M. R.
    Bornhauser, M.
    Bredeson, C. N.
    Cairo, M. S.
    Copelan, E. A.
    Gale, R. P.
    Giralt, S. A.
    Gulbas, Z.
    Gupta, V.
    Hale, G. A.
    Lazarus, H. M.
    Lewis, V. A.
    Lill, M. C.
    McCarthy, P. L.
    Weisdorf, D. J.
    Pulsipher, M. A.
    BONE MARROW TRANSPLANTATION, 2012, 47 (02) : 203 - 211
  • [25] Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDS patients in first complete remission
    Shahjahan, M
    Alamo, J
    de Lima, M
    Khouri, I
    Gajewski, J
    Andersson, B
    Champlin, R
    Giralt, SM
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 12 - 13
  • [26] Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS
    Radford, Michael
    Garcia-Horton, Alejandro
    Badami, Rohail
    Jin, Elaine
    Usmani, Nida
    Grafodatskaya, Daria
    Mccready, Elizabeth
    Khalaf, Dina
    Walker, Irwin
    Leber, Brian
    Lepic, Kylie
    Pond, Gregory
    Berg, Tobias
    TRANSPLANTATION AND CELLULAR THERAPY, 2025, 31 (02): : 77e1 - 77e20
  • [27] Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
    S M Luger
    O Ringdén
    M-J Zhang
    W S Pérez
    M R Bishop
    M Bornhauser
    C N Bredeson
    M S Cairo
    E A Copelan
    R P Gale
    S A Giralt
    Z Gulbas
    V Gupta
    G A Hale
    H M Lazarus
    V A Lewis
    M C Lill
    P L McCarthy
    D J Weisdorf
    M A Pulsipher
    Bone Marrow Transplantation, 2012, 47 : 203 - 211
  • [28] Obesity does not impact outcome in patients with AML/MDS undergoing allogeneic transplantation
    De Padua Silva, Leandro
    Saliba, Rima. M.
    de Lima, Marcos
    Okoroji, Grace J.
    Alousi, Athin
    Andersson, Borje
    Hosing, Chitra
    Sphall, Elizabeth
    Khuri, Issa
    Qazilbash, Muzaffar
    Anderlini, Paolo
    Kebriaei, Partow
    Champlin, Richard E.
    Jones, Roy
    Biralt, Sergio
    Popat, Uday
    BLOOD, 2007, 110 (11) : 592A - 592A
  • [29] IMPACT OF TP53 MUTATION ON OUTCOME OF MDS PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT (HSCT). GESMD STUDY
    Diez Campelo, M.
    Caballero, J. C.
    Sanchez Barba, M.
    Del Rey, M.
    Janusz, K.
    Lumbreras, E.
    Abaigar, M.
    Robledo, C.
    Jerez, A.
    Calderon-Cabrera, C.
    Such, E.
    Cervera, J.
    Sanz, G.
    Valcarcel, D.
    Hernandez-Rivas, J. M.
    Del Canizo, C.
    LEUKEMIA RESEARCH, 2015, 39 : S102 - S103
  • [30] Impact of prior solid tumor on outcomes of allogeneic hematopoietic stem cell transplantation for AML or MDS.
    Albittar, Aya
    Portuguese, Andrew Jay
    Gooley, Ted
    Deeg, H. Joachim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345